Skip to content

Clinical Study on the Effects of Remimazolam on Thermoregulation and Shivering in Elderly Patients

Clinical Study on the Effects of Remimazolam on Thermoregulation and Shivering in Elderly Patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600115967
Enrollment
Unknown
Registered
2026-01-04
Start date
2026-01-05
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Perioperative hypothermia and shivering

Interventions

R group:Before anesthesia induction, remimazolam was intravenously pumped at a dose of 0.2 mg/kg. Then, anesthesia induction was performed using etomidate (0.1-0.3 mg/kg), sufentanil (0.3-0.5 µg/kg),
D group:Dexmedetomidine was intravenously pumped at a dose of 0.5 µg/kg before anesthesia induction, and the subsequent anesthesia induction was the same as that in the remimazolam group. During anest
C group:An equal amount of normal saline was intravenously pumped during induction and maintenance of anesthesia.

Sponsors

Chengdu Pidu District People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1 Aged 65-80 years, gender not limited; 2 Scheduled to undergo laparoscopic radical resection of gastrointestinal tumors under general anesthesia; 3 ASA grade II-III; 4 Patients are willing and able to provide a signed informed consent form before any study-related procedures are performed.

Exclusion criteria

Exclusion criteria: 1 Abnormal initial body temperature, such as = 37.5 °C; 2 Body Mass Index (BMI) > 30 kg/m^² or combined with diseases affecting body temperature, such as abnormal thyroid function, pituitary tumors, history of infectious fever within 2 weeks, etc.; 3 Expected operation time < 120 minutes; 4 History of severe cardiovascular, respiratory, liver or kidney dysfunction before surgery; 5 Allergy to remimazolam or dexmedetomidine; 6 Inability to cooperate in completing this study, such as mental illness, language difficulties, disturbance of consciousness, etc.; 7 Participation in other clinical trials within 1 month.

Design outcomes

Primary

MeasureTime frame
The incidence and severity of PAS 15 minutes after admission to the post-anesthesia care unit;

Secondary

MeasureTime frame
The incidence of hypothermia during surgery and in the PACU period;Core temperatures at multiple time points;The expression level of NE in serum;

Countries

China

Contacts

Public ContactLi JunXiang

Chengdu Pidu District People's Hospital

494973600@qq.com+86 183 4930 1952

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026